Chronic Metformin Treatment is Associated with Reduced Myocardial Infarct Size in Diabetic Patients with ST-segment Elevation Myocardial Infarction

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cardiovascular Drugs and Therapy

• Publication date

  2014-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10557-013-6504-7PMID 24292206
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic pretreatment of metformin is associated with the reduction of the no-reflow phenomenon in patients with diabetes mellitus after primary angioplasty for acute myocardial infarction.

  2013influential reference
• Chronic Metformin Associated Cardioprotection Against Infarction: Not Just a Glucose Lowering Phenomenon

  2013cited by this paper
• Population trends in percutaneous coronary intervention: 20-year results from the SCAAR (Swedish Coronary Angiography and Angioplasty Registry).

  2013cited by this paper
• ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

  2012cited by this paper
• Effects of metformin on insulin resistance in heart failure. Which came first: the chicken or the egg?

  2012cited by this paper
• ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation.

  2012cited by this paper
• Metformin Prevents the Development of Chronic Heart Failure in the SHHF Rat Model

  2012cited by this paper
• Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry

  2012cited by this paper
• The Diabetic Heart: Too Sweet for Its Own Good?

  2012cited by this paper
• Exenatide Reduces Final Infarct Size in Patients With ST-Segment–Elevation Myocardial Infarction and Short-Duration of Ischemia

  2012cited by this paper
• Metformin in non-Diabetic Patients Presenting with ST Elevation Myocardial Infarction: Rationale and Design of the Glycometabolic Intervention as Adjunct to Primary Percutaneous Intervention in ST Elevation Myocardial Infarction (GIPS)-III Trial

  2012cited by this paper
• Metformin overdose causes platelet mitochondrial dysfunction in humans

  2012cited by this paper
• Prognostic Value of Admission Glycosylated Hemoglobin and Glucose in Nondiabetic Patients With ST-Segment–Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention

  2011cited by this paper
• Standards of Medical Care in Diabetes—2011

  2011cited by this paper
• Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure.

  2011influential reference
• The cardioprotective effects of metformin

  2011cited by this paper
• Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin–Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study

  2011cited by this paper
• Metformin: taking away the candy for cancer?

  2010cited by this paper
• Relationship of dysglycemia to acute myocardial infarct size and cardiovascular outcome as determined by cardiovascular magnetic resonance

  2010cited by this paper
• Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.

  2009cited by this paper
• Investigation of the effect of oral metformin on dipeptidylpeptidase‐4 (DPP‐4) activity in Type 2 diabetes 1

  2009cited by this paper
• Metformin Prevents Myocardial Reperfusion Injury by Activating the Adenosine Receptor

  2009influential reference
• Activation of AMP-Activated Protein Kinase by Metformin Improves Left Ventricular Function and Survival in Heart Failure

  2009influential reference
• Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening

  2008cited by this paper
• Metformin: Effects on Micro and Macrovascular Complications in Type 2 Diabetes

  2008cited by this paper
• Acute Metformin Therapy Confers Cardioprotection Against Myocardial Infarction Via AMPK-eNOS–Mediated Signaling

  2008cited by this paper
• The importance of left ventricular function for long-term outcome after primary percutaneous coronary intervention

  2008cited by this paper
• Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration.

  2008cited by this paper
• The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients.

  2008cited by this paper
• Prognostic value of admission glucose in non-diabetic patients with myocardial infarction.

  2004cited by this paper
• Magnetic Resonance and Computed Tomographic Imaging Gadolinium Delayed Enhancement Cardiovascular Magnetic Resonance Correlates With Clinical Measures of Myocardial Infarction

  2004cited by this paper
• The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis.

  2002cited by this paper
• Plasminogen Activator Inhibitor‐1: Physiologic Role, Regulation, and the Influence of Common Pharmacologic Agents

  2002cited by this paper
• Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.

  2000cited by this paper
• Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)

  1998cited by this paper
• Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase*

  1987cited by this paper
• Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

  1987cited by this paper
• A reporting system on patients evaluated for coronary artery disease. Report of the Ad Hoc Committee for Grading of Coronary Artery Disease, Council on Cardiovascular Surgery, American Heart Association.

  1975cited by this paper

• Unraveling genetic causality between metformin and myocardial infarction on the basis of Mendelian randomization

  2024cites this paper
• Metformin's cardioprotective role in isoprenaline-induced myocardial infarction: Unveiling insights into the AMPK, NF-κB, JAK2/STAT3 pathways, and cholinergic regulation.

  2024cites this paper
• Emerging opportunities to target inflammation: myocardial infarction and type 2 diabetes

  2024cites this paper
• Investigation of Anti-inflammatory, Antioxidative, and Cardioprotective Effects of Combined Metformin and Exercise in Rats

  2024cites this paper
• Novel Approaches to the Management of Diabetes Mellitus in Patients with Coronary Artery Disease.

  2023cites this paper
• Old and Novel Therapeutic Approaches in the Management of Hyperglycemia, an Important Risk Factor for Atherosclerosis

  2022cites this paper
• Evaluation of selected antidiabetics in cardiovascular complications associated with cancer cachexia

  2022cites this paper
• Association of Metformin with the Mortality and Incidence of Cardiovascular Events in Patients with Pre-existing Cardiovascular Diseases

  2022cites this paper
• Effect of metformin on adverse outcomes in T2DM patients: Systemic review and meta-analysis of observational studies

  2022cites this paper
• Effect of Metformin on T2D-Induced MAM Ca2+ Uncoupling and Contractile Dysfunction in an Early Mouse Model of Diabetic HFpEF

  2022cites this paper
• Cardiovascular outcomes associated with treatment of type 2 diabetes in patients with ischaemic heart failure

  2022cites this paper
• COVID-19: Can Metformin Drastically Reduce the Number of Deaths?

  2021cites this paper
• The Current and Potential Therapeutic Use of Metformin—The Good Old Drug

  2021cites this paper
• Myocardial Ischemia-Reperfusion and Diabetes: Lessons Learned From Bedside to Bench

  2021cites this paper
• Myocardial remote ischemic preconditioning: from cell biology to clinical application

  2021cites this paper
• RRCC_A_313432 1..7

  2021cites this paper
• New Perceptions in the Cardioprotective Effect of Metformin Against Isoproterenol Induced Cardiotoxicity in Male Rats

  2021cites this paper
• Kolaviron attenuates cardiovascular injury in fructose-streptozotocin induced type-2 diabetic male rats by reducing oxidative stress, inflammation, and improving cardiovascular risk markers.

  2021cites this paper
• Cardiac Troponin-I Status of Type-2 Diabetic Patients on Anti-Diabetic Drugs Treatment at Jimma Medical Center, Jimma, Southwest Ethiopia

  2021cites this paper
• Metformin upregulates the expression of Gli1 in vascular endothelial cells in hyperoxia-exposed neonatal mice.

  2020cites this paper
• Co‐morbidities and co‐medications as confounders of cardioprotection—Does it matter in the clinical setting?

  2020cites this paper
• Metformin Preconditioning Improves Hepatobiliary Function and Reduces Injury in a Rat Model of Normothermic Machine Perfusion and Orthotopic Transplantation

  2020cites this paper
• Pharmacological preconditioning protects from ischemia/reperfusion‐induced apoptosis by modulating Bcl‐xL expression through a ROS‐dependent mechanism

  2020cites this paper
• Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis

  2019cites this paper
• Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study

  2019cites this paper
• Recurrent cardiovascular events in patients with newly diagnosed acute coronary syndrome: Influence of diabetes and its management with medication.

  2019cites this paper
• New advances in perioperative cardioprotection

  2019cites this paper
• Effects of metformin on the heart with ischaemia-reperfusion injury: Evidence of its benefits from in vitro, in vivo and clinical reports.

  2019cites this paper
• The impact of metformin on cardiovascular markers in type 1 diabetes :MERIT study

  2018cites this paper
• Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association–European Society of Cardiology

  2018cites this paper
• Proangiogenic Effect of Metformin in Endothelial Cells Is via Upregulation of VEGFR1/2 and Their Signaling under Hyperglycemia-Hypoxia

  2018cites this paper
• Evaluation of metformin effects in the chronic phase of spontaneous seizures in pilocarpine model of temporal lobe epilepsy

  2018cites this paper
• Cardioprotective Effects of Metformin

  2018cites this paper
• Anti-Angiogenic miR-222, miR-195, and miR-21a Plasma Levels in T1DM Are Improved by Metformin Therapy, Thus Elucidating Its Cardioprotective Effect: The MERIT Study

  2018cites this paper
• Effect of metformin on cardiac function in patients with STEMI : a systematic review and meta-analysis

  2018cites this paper
• Translation, Translation, Translation.

  2018cites this paper
• Metformin is not associated with lactic acidosis in patients with diabetes undergoing coronary artery bypass graft surgery: a case control study

  2017cites this paper
• Metformin effects on the heart and the cardiovascular system: A review of experimental and clinical data.

  2017cites this paper
• Two-year follow-up of 4 months metformin treatment vs. placebo in ST-elevation myocardial infarction: data from the GIPS-III RCT

  2017influential citation
• Mitochondrial hexokinase and ischemic sensitivity and metabolism of the heart

  2017cites this paper
• The burden of myocardial infarction

  2017cites this paper
• Metformin attenuates ER stress–induced mitochondrial dysfunction

  2017cites this paper
• Sulfonylurea use is associated with larger infarct size in patients with diabetes and ST-elevation myocardial infarction.

  2016cites this paper
• Metformin improves circulating endothelial cells and endothelial progenitor cells in type 1 diabetes: MERIT study

  2016cites this paper
• The Effect of Metformin on Diastolic Function in Patients Presenting with ST-Elevation Myocardial Infarction

  2016cites this paper
• Comparative Impact of Hypoglycemic Agents on Severity and Extent of Myocardial Ischemia in Patients With Type 2 Diabetes Mellitus Undergoing Myocardial Perfusion Scintigraphy

  2016cites this paper
• Effects of dipeptidyl peptidase-4 inhibitor in insulin-resistant rats with myocardial infarction.

  2016cites this paper
• Targeting the adenosine system to limit ischemia-reperfusion injury : translational research in humans

  2016cites this paper
• The effects of intravenous insulin infusions on early mortality for patients with acute coronary syndromes who present with hyperglycaemia: A matched propensity analysis using data from the MINAP database 2008–2012

  2015cites this paper
• Effect of metformin on outcome in patients undergoing primary percutaneous coronary intervention for st-segment elevation myocardial infarction

  2015cites this paper
• Metformin and Myocardial Injury in Patients With Diabetes and ST‐Segment Elevation Myocardial Infarction: A Propensity Score Matched Analysis

  2015influential citation
• Dipeptidyl peptidase‐4 inhibitor improves cardiac function by attenuating adverse cardiac remodelling in rats with chronic myocardial infarction

  2015cites this paper
• The pleiotropic effects of metformin: time for prospective studies

  2015cites this paper
• Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease

  2015cites this paper
• The Effect of Metformin Use on Left Ventricular Ejection Fraction and Mortality Post-Myocardial Infarction

  2015cites this paper
• Effect of metformin pretreatment on myocardial injury during coronary artery bypass surgery in patients without diabetes (MetCAB): a double-blind, randomised controlled trial.

  2015cites this paper
• Metformin and preservation of left ventricular function

  2015cites this paper
• Metformina: un arma noble para tiempos más civilizados

  2015cites this paper
• Metformine et post-infarctus du myocarde : intérêt sur la fonction ventriculaire gauche chez le patient non diabétique ?

  2015cites this paper
• Non-alcoholic Fatty Liver Disease

  2014cites this paper
• The Role of Non-alcoholic Fatty Liver Disease in Cardiovascular Disease.

  2014cites this paper
• Effect ofMetformin on Left Ventricular Function After AcuteMyocardial Infarction in PatientsWithout Diabetes The GIPS-III Randomized Clinical Trial

  2014cites this paper
• Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial.

  2014cites this paper
• The cardiovascular effects of metformin: lost in translation?

  2014cites this paper
• of metformin on mortality and cardiovascular events in patients with pre-existing

  year unknowncites this paper